Healthcare entity
All 1 tracked stories fall under one category: market-trends. Of the tracked stories, 1 of 1 also mention Catalyst Pharmaceuticals, the most common co-covered peer. Their average consequence score of 5 runs below the beat's 6 for that window. Each story carries 2 original sources on average, compared with 2.4 for the broader beat in this window.
Last mentioned: Feb 24, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: market-trends. Of the tracked stories, 1 of 1 also mention Catalyst Pharmaceuticals, the most common co-covered peer. Their average consequence score of 5 runs below the beat's 6 for that window. Each story carries 2 original sources on average, compared with 2.4 for the broader beat in this window. We currently track 1 Healthcare story that mention Agamree, all published on February 24, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 26 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Agamree. Shared-story counts are live from our verified record — not editorial picks.
Root and Catalyst Pharmaceuticals are scheduled to release their quarterly financial results this Wednesday, providing critical data points for the insurtech and orphan drug sectors. Investors are looking for Root's progress toward profitability and Catalyst's continued dominance in the LEMS market.
Source: tickerreport.com · dailypolitical.com
Agamree is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
